Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3.
Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3.
复制标题
DOI：
10.1016/j.esmoop.2021.100203
复制
发表时间：
2021-08
期刊：
影响因子：
7.3
通讯作者：
Wildiers H
中科院分区：
文献类型：
--
作者：
De Cock L;Heylen J;Wildiers A;Punie K;Smeets A;Weltens C;Neven P;Billen J;Laenen A;Wildiers H
目前大多数指南不推荐在无症状早期乳腺癌（EBC）患者的随访中进行肿瘤标志物ca15.3的系列分析。这些指南是基于在治疗选择比今天更有限的时代进行的小规模研究。在我们的大型学术中心，在EBC的随访中常规使用ca15.3的连续测量，而远处转移的影像学仅根据指征进行。在这项回顾性单中心研究中，如果患者在2000年1月1日至2018年1月1日期间接受过EBC治疗，在初次手术后至少6个月被诊断为继发性转移性疾病，并且在诊断转移时可获得CA 15.3，则纳入患者。主要目的是评估发现转移性疾病的患者比例（CA升高15.3）。经伦理委员会批准，收集转移检测方法、CA 15.3进化和生存信息。在诊断转移时，730例患者中有451例（62%）的CA 15.3水平高于正常上限（bbb30 kU/l）。在269例患者（37%）中，CA 15.3升高是导致转移诊断的第一个迹象。这在腔内a样肿瘤（48%）、肝脏（45%）和骨骼（41%）转移灶中最为常见。相比之下，报告的症状在48%的患者中引发了转移性疾病的诊断。当CA 15.3升高发现复发时，中位总生存期明显高于其他触发因素（异常临床检查或病史、异常实验室检查或偶然发现）发现复发的患者（35个月vs 22个月；P = 0.0027）。当在EBC患者的随访中系统地使用ca15.3时，由于ca15.3的增加，转移性疾病的诊断率为37%。当接受EBC治疗的患者常规随访CA 15.3时，37%的患者CA 15.3升高是转移的第一个迹象。在诊断转移时，62%的患者CA 15.3水平高于正常上限（30ku /l）。报告的症状仍然是最重要的指标，并导致48%的患者诊断为转移。
Most current guidelines do not recommend the serial analysis of tumour marker CA 15.3 in the follow-up of asymptomatic patients treated for early breast cancer (EBC). These guidelines are based on small-scale studies carried out in an era with more limited treatment options than today. In our large academic centre, serial measurements of CA 15.3 are used routinely in the follow-up of EBC, whereas imaging for distant metastases is only carried out on indication. In this retrospective single-centre study, patients were included if they were treated for EBC between 1 January 2000 and 1 January 2018, diagnosed with secondary metastatic disease at least 6 months after initial surgery and had CA 15.3 available at the time of diagnosis of metastases. The primary objective was to evaluate the proportion of patients in whom metastatic disease was discovered by an increasing CA 15.3. Information on the method of metastases detection, CA 15.3 evolution and survival was collected after approval of the ethics committee. At the moment of diagnosis of metastases, 451 of 730 included patients (62%) had CA 15.3 levels above the upper limit of normal (>30 kU/l). In 269 patients (37%), an increasing CA 15.3 was the first sign that led to the diagnosis of metastases. This was most frequent in luminal A-like tumours (48%) and in liver (45%) and bone (41%) localisation of metastases. By contrast, reported symptoms triggered the diagnosis of metastatic disease in 48% of the patients. Median overall survival was significantly longer when the relapse was discovered by CA 15.3 elevation versus those discovered by another trigger (abnormal clinical examination or history, abnormal laboratory tests or an incidental finding) (35 versus 22 months; P = 0.0027). When CA 15.3 is systematically used in the follow-up of EBC patients, the diagnosis of metastatic disease is made in 37% by a CA 15.3 increase. When CA 15.3 is routinely followed in patients treated for EBC, CA 15.3 elevation is the first sign of metastases in 37%. At the moment of diagnosis of metastases, 62% of the patients had CA 15.3 levels above the upper limit of normal (>30 kU/l). Reported symptoms remain the most important indicator and led to the diagnosis of metastases in 48% of the patients.
登录
查看更多内容
影响因子：
3.7
作者：
Joseph, E;Hyacinthe, M;Cox, CE
通讯作者：
Cox, CE
影响因子：
6.2
作者：
Pentheroudakis, G;Malamou-Mitsi, V;Pavlidis, N
通讯作者：
Pavlidis, N
影响因子：
3.8
作者：
Kokko, R;Hakama, M;Holli, K
通讯作者：
Holli, K
影响因子：
45.3
作者：
Allison, Kimberly H.;Hammond, M. Elizabeth H.;Wolff, Antonio C.
通讯作者：
Wolff, Antonio C.
DOI：
10.1186/s13058-017-0909-3
发表时间：
2017-11-07
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Brouckaert O;Rudolph A;Laenen A;Keeman R;Bolla MK;Wang Q;Soubry A;Wildiers H;Andrulis IL;Arndt V;Beckmann MW;Benitez J;Blomqvist C;Bojesen SE;Brauch H;Brennan P;Brenner H;Chenevix-Trench G;Choi JY;Cornelissen S;Couch FJ;Cox A;Cross SS;Czene K;Eriksson M;Fasching PA;Figueroa J;Flyger H;Giles GG;González-Neira A;Guénel P;Hall P;Hollestelle A;Hopper JL;Ito H;Jones M;Kang D;kConFab;Knight JA;Kosma VM;Li J;Lindblom A;Lilyquist J;Lophatananon A;Mannermaa A;Manoukian S;Margolin S;Matsuo K;Muir K;Nevanlinna H;Peterlongo P;Pylkäs K;Saajrang S;Seynaeve C;Shen CY;Shu XO;Southey MC;Swerdlow A;Teo SH;Tollenaar RAEM;Truong T;Tseng CC;van den Broek AJ;van Deurzen CHM;Winqvist R;Wu AH;Yip CH;Yu JC;Zheng W;Milne RL;Pharoah PDP;Easton DF;Schmidt MK;Garcia-Closas M;Chang-Claude J;Lambrechts D;Neven P
通讯作者：
Neven P